山东大学学报 (医学版) ›› 2024, Vol. 62 ›› Issue (3): 107-111.doi: 10.6040/j.issn.1671-7554.0.2024.0124
许沛晨1,李晓博1,2,庄向华1,2,娄能俊1,2,吕丽1,2,周玲雁1,2,牟亚朋1,宋玉文1,2*,陈诗鸿1,2*
中图分类号:
| [1] Alstrom CH, Hallgren B, Nilsson LB, et al. Retinal degeneration combined with obesity, diabetes mellitus and neurogenous deafness: a specific syndrome(not hitherto described)distinct from the Laurence-Moon-Bardet-Biedl syndrome: a clinical, endocrinological and genetic examination based on a large pedigree[J]. Acta Psychiatr Neurol Scand Suppl, 1959, 129:1-35. [2] Zhang Q, Ding Y, Feng B, et al. Molecular and phenotypic expansion of Alström Syndrome in Chinese patients[J]. front genet, 2022, 13:808919. doi: 10.3389/fgene.2022.808919. [3] 王云芳,万小艳,牛瑞兰,等.Alstrom综合征两例报道[J].中国糖尿病杂志, 2023, 31(2): 139-144. WANG Yunfang, WAN Xiaoyan, NIU Ruilan, et al. Chinese Journal of Diabetes Mellitus, 2023, 31(2): 139-144. [4] Hearn T, Renforth GL, Spalluto C, et al. Mutation of ALMS1, a large gene with a tandem repeat encoding 47 amino acids, causes Alström syndrome[J]. Nat Genet, 2002, 31(1): 79-83. [5] 付宇,王金堂.Alstrom综合征的发病机制及诊治研究进展[J].山东医药, 2019, 59(18): 87-91. [6] Jagger D, Collin G, Kelly J, et al. Alström Syndrome protein ALMS1 localizes to basal bodies of cochlear hair cells and regulates cilium-dependent planar cell polarity[J]. Hum Mol Genet, 2011, 20(3): 466-481. [7] Hearn T. ALMS1 and Alström syndrome: a recessive form of metabolic, neurosensory and cardiac deficits[J]. J Mol Med(Berl), 2019, 97(1): 1-17. [8] Favaretto F, Milan G, Collin GB, et al. GLUT4 defects in adipose tissue are early signs of metabolic alterations in Alms1GT/GT, a mouse model for obesity and insulin resistance[J]. PLoS One, 2014, 9(10): e109540. doi: 10.1371/journal.pone.0109540. [9] Monu SR, Potter DL, Liao TD, et al. Role of Alström syndrome 1 in the regulation of glomerular hemodynamics[J]. Am J Physiol Renal Physiol, 2023, 325(4): F418-f425. [10] Baig S, Paisey R, Dawson C, et al. Defining renal phenotype in Alström syndrome[J]. Nephrol Dial Transplant, 2020, 35(6): 994-1001. [11] Ademolu AB, Geberhiwot T. Hematopoietic stem cell progenitors driving metabolic disturbance in Alström Syndrome[J]. Endocrinology, 2023, 164(9): bqad110. [12] Quoraishi S, Mason G, Geberhiwot T, et al. Hearing loss in adults with Alström Syndrome-experience from the UK National Alström Service[J]. Otol Neurotol, 2022, 43(6): e620-e627. [13] Tahani N, Maffei P, Dollfus H, et al. Consensus clinical management guidelines for Alström syndrome[J]. Orphanet J Rare Dis, 2020, 15(1): 253. [14] Wang Y, Huang L, Sun L, et al. Ocular findings and genetic test in Alström syndrome in childhood[J]. Exp Eye Res, 2022, 225: 109277. [15] 张倩文, 丁宇, 常国营, 等. 2020年欧洲Alström综合征临床管理指南介绍及解读[J]. 中华实用儿科临床杂志, 2021, 36(13): 961-965. ZHANG Qianwen,DING Yu,CHANG Guoying,et al. Introduction and interpretation of European clinical management guidelines for Alström syndrome in 2020[J]. Chinese Journal of Applied Clinical Pediatrics, 2021, 36(13): 961-965. [16] Nerakh G, Ranganath P. Alström Syndrome presenting as isolated dilated cardiomyopathy[J]. Indian J Pediatr, 2019, 86(3): 296-298. [17] Dedeoglu S, Dede E, Oztunc F, et al. Mutation identification and prediction for severe cardiomyopathy in Alström syndrome, and review of the literature for cardiomyopathy[J]. Orphanet J Rare Dis, 2022, 17(1): 359. [18] Herranz-Heras JC, Barceló A, Quesada-Espinosa JF, et al. Alström syndrome: two clinical cases with two novel pathogenic variants[J]. Eur J Ophthalmol, 2023, 33(4): Np27-np31. [19] Marshall JD, Muller J, Collin GB, et al. Alström Syndrome: mutation spectrum of ALMS1[J]. Hum Mutat, 2015, 36(7): 660-668. [20] Zhou C, Xiao Y, Xie H, et al. A novel variant in ALMS1 in a patient with Alström syndrome and prenatal diagnosis for the fetus in the family: a case report and literature review[J]. Mol Med Rep, 2020, 22(4): 3271-3276. [21] Abosabie SAS, Abosabie SA, Alfaifi J, et al. Unraveling Alström syndrome: homozygous mutation c.2729C>G in ALMS1 gene across an extended family[J]. Mol Genet Genomic Med, 2024, 12(1): e2314. [22] Bea-Mascato B, Valverde D. Genotype-phenotype associations in Alström syndrome: a systematic review and meta-analysis[J]. J Med Genet, 2023, 61(1): 18-26. [23] Engle SE, Bansal R, Antonellis PJ, et al. Cilia signaling and obesity[J]. Semin Cell Dev Biol, 2021, 110: 43-50. [24] Littleton SH, Berkowitz RI, Grant SFA. Genetic determinants of childhood obesity[J]. Mol Diagn Ther, 2020, 24(6): 653-663. [25] Dassie F, Favaretto F, Bettini S, et al. Alström syndrome: an ultra-rare monogenic disorder as a model for insulin resistance, type 2 diabetes mellitus and obesity[J]. Endocrine, 2021, 71(3): 618-625. [26] Kang S. Adipose tissue malfunction drives metabolic dysfunction in Alström Syndrome[J]. Diabetes, 2021, 70(2): 323-325. [27] Geberhiwot T, Baig S, Obringer C, et al. Relative adipose tissue failure in Alström Syndrome drives obesity-induced insulin resistance[J]. Diabetes, 2021, 70(2): 364-376. [28] Frölander HE, Möller C, Rudner M, et al. Theory-of-mind in individuals with Alström syndrome is related to executive functions, and verbal ability[J]. Front Psychol, 2015, 6: 1426. doi: 10.3389/fpsyg.2015.01426. eCollection 2015. [29] Bettini S, Bombonato G, Dassie F, et al. Liver fibrosis and steatosis in Alström Syndrome: a genetic model for metabolic syndrome[J]. Diagnostics(Basel), 2021, 11(5). doi: 10.3390/diagnostics11050797. [30] Marshall JD, Bronson RT, Collin GB, et al. New Alström syndrome phenotypes based on the evaluation of 182 cases[J]. Arch Intern Med, 2005, 165(6): 675-683. [31] Brofferio A, Sachdev V, Hannoush H, et al. Characteristics of cardiomyopathy in Alström syndrome: prospective single-center data on 38 patients[J]. Mol Genet Metab, 2017, 121(4): 336-343. [32] Aksoy F, Ozgur T, Dundar HZ, et al. Liver transplantation in Alstrom Syndrome: a case report[J]. Exp Clin Transplant, 2021. doi: 10.6002/ect.2020.0006. [33] Gheller F, Gallo S, Trevisi P, et al. Cochlear implants in Alström Syndrome[J]. Ann Otol Rhinol Laryngol, 2020, 129(8): 833-837. [34] Baig S, Veeranna V, Bolton S, et al. Treatment with PBI-4050 in patients with Alström syndrome: study protocol for a phase 2, single-Centre, single-arm, open-label trial[J]. BMC Endocr Disord, 2018, 18(1): 88. [35] Haqq AM, Chung WK, Dollfus H, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period[J]. Lancet Diabetes Endocrinol, 2022, 10(12): 859-868. |
| [1] | 张媛 李英敏 冯月秋 常彩云 潘华伟 王束玫. 血清脂联素水平与肥胖、胰岛素抵抗的关系探讨[J]. 山东大学学报(医学版), 2209, 47(6): 124-. |
| [2] | 赵万霞,詹群璋,金婷,刘玉新,曲崇正,吴剑纯. 基于孟德尔随机化分析肠道菌群、血液代谢物和肥胖的因果关系[J]. 山东大学学报 (医学版), 2026, 64(4): 72-82. |
| [3] | 孟晓梅,郝亚平,王亮,于晓,唐与晓. 血清Isthmin1、Gremlin2水平与2型糖尿病患者视网膜病变的相关性[J]. 山东大学学报 (医学版), 2025, 63(9): 102-107. |
| [4] | 王梦星,薛付忠,杨帆. 基于多模态交叉注意力机制融合的1型糖尿病血糖浓度预测方法[J]. 山东大学学报 (医学版), 2025, 63(8): 41-50. |
| [5] | 申路佳,逯天威,巩伟明,赵岩松,王淑康,袁中尚. 代谢风险评分在2型糖尿病人群心血管结局预测中的应用[J]. 山东大学学报 (医学版), 2025, 63(8): 69-78. |
| [6] | 陈莹莹,王鲁,胡锡峰,朱高培,薛付忠. 基于贝叶斯网络的2型糖尿病患者并发脑卒中风险预测[J]. 山东大学学报 (医学版), 2025, 63(8): 94-102. |
| [7] | 陈绪军, 何国伟. 着力进一步推进动脉桥在我国冠心病冠脉旁路移植术中的应用[J]. 山东大学学报 (医学版), 2025, 63(5): 1-5. |
| [8] | 卢圣勋,邢亚闯,罗俊辉,刘杰,何厚乐,王志强,张娜. 糖尿病患者冠脉旁路移植手术中动脉桥的研究现状[J]. 山东大学学报 (医学版), 2025, 63(5): 33-39. |
| [9] | 杜学识,倪向敏,梁馨予,白倩,朱文艺,王建. 雌马酚对DN的保护作用及潜在靶点[J]. 山东大学学报 (医学版), 2024, 62(8): 49-58. |
| [10] | 刘淋,王晓楠,杨雅溪,王江腾,李旭,周新丽,管庆波,张栩. 甘油三酯-葡萄糖指数与颅内动脉粥样硬化性狭窄的相关性[J]. 山东大学学报 (医学版), 2024, 62(8): 93-100. |
| [11] | 冯悦,俞一凡,吴思佳,李洪凯,薛付忠. 内脏脂肪组织与肺部疾病的孟德尔随机化研究[J]. 山东大学学报 (医学版), 2024, 62(7): 48-55. |
| [12] | 刘雯,冯文娟,杨阳,纪昌丽,晁岚. 体质量指数对卵巢正常反应患者累积分娩率的影响[J]. 山东大学学报 (医学版), 2024, 62(3): 54-60. |
| [13] | 梁中昊,庄向华,黄珊,韩晓琳,华梦羽,琚丽萍,陈诗鸿. 饮食诱导肥胖雌鼠棕色脂肪组织蛋白质组学分析[J]. 山东大学学报 (医学版), 2024, 62(2): 10-19. |
| [14] | 林晓倩,封茂燕,牟正. 二肽基肽酶-4抑制剂的药学特点及临床应用[J]. 山东大学学报 (医学版), 2024, 62(12): 43-48. |
| [15] | 范佳旭, 成芳,乔俊鹏,费海程,陈学禹,赵云,贾红英. 中介或混杂因素:是否应调整肥胖以估计三卤甲烷对甲状腺功能的影响[J]. 山东大学学报 (医学版), 2024, 62(1): 102-110. |
|
||
